RedHill Biopharma Ltd. (NASDAQ:RDHL) does about 3.25M shares in volume on a normal day but saw 2206972 shares change hands in Monday trading. The company now has a market cap of 15.42M USD. Its current market price is $0.17, marking a decrease of -0.87% compared to the previous close of $0.17. The 52 week high reached by this stock is $3.27 whilst the lowest price level in 52 weeks is $0.13. The script in recent trading has seen the stock touch a high of $0.175 and a low of $0.17.
RedHill Biopharma Ltd. (RDHL) has a 20-day trading average at $0.1656 and the current price is -94.77% off the 52-week high compared with 35.71% distance from its 52-week low. The 50-day simple moving average of the closing price is $0.2731 and its 200-day simple moving average is $0.8147. If we look at the stock’s price movements over the week, volatility stands at 7.51%, which increases to 9.95% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 38.01 to suggest the stock is neutral.
The consensus objective for the share price is $2.75, suggesting that the stock has a potential upside of 93.82% over the period. The median price target is 83.0% away from the current levels at $1.00.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on August 31, 2021 when Cantor Fitzgerald initiated the stock to “Overweight” and issued a price target of $22.
The current price level is 3.48%, -39.39%, and -79.31% away from its SMA20, SMA50, and SMA200 respectively, with the RDHL price moving above the 50-day SMA on January 23. RedHill Biopharma Ltd. (RDHL) stock is down -13.42% over the week and 0.59% over the past month. Its price is 21.88% year-to-date and -94.10% over the past year.
The stock last released its quarterly earnings report for quarter ended 3/30/2022, with the company’s earnings per share (EPS) of -$0.3 below consensus estimates by -$0.07. The company’s next earnings report is expected on 05/09/2023, with forecasts estimating quarterly EPS at -$0.03 and -$0.13 for whole year. Expected sales for next quarter are $23.19 million, which analysts say will come at $88.4 million for the current fiscal year and next year at $105.86 million. In addition, estimates put the company’s current quarterly revenue at an average of $21.5 million.
Its 12-month price target is $1.00. To reach the target analysts have set, the stock logically needs to grow 93.82 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $1.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $1.00.
Outstanding shares total 63.84M with insiders holding 12.95% of the shares and institutional holders owning 9.66% of the company’s common stock. The company has a return on investment of -83.90% and return on equity of 679.60%. The beta has a value of 2.13. Price to sales ratio is 0.22.
FCP Medical – BioHealth isn’t the only investment manager who changed stakes and is followed by APO Medical Opportunities, which added 0.34 million shares to end up with 720,776 shares worth $0.1 million.